The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs.
Recently, the imidazolinone derivative imepitoin has been approved for treatment of canine epilepsy. Imepitoin acts as a low-affinity partial agonist at the benzodiazepine (BZD) site of the GABAA receptor and is the first compound with such mechanism that has been developed as an antiepileptic drug (AED). This mechanism offers several advantages compared to full agonists, including less severe adverse effects and a lack of tolerance and dependence liability, which has been demonstrated in rodents, dogs, and nonhuman primates. In clinical trials in epileptic dogs, imepitoin was shown to be an effective and safe AED. Recently, seizures in dogs have been proposed as a translational platform for human therapeutic trials on new epilepsy treatments. In the present study, we compared the anticonvulsant efficacy of imepitoin, phenobarbital and the high-affinity partial BZD agonist abecarnil in the timed i.v. pentylenetetrazole (PTZ) seizure threshold test in dogs and, for comparison, in mice. Furthermore, adverse effects of treatments were compared in both species. All drugs dose-dependently increased the PTZ threshold in both species, but anticonvulsant efficacy was higher in dogs than mice. At the doses selected for this study, imepitoin was slightly less potent than phenobarbital in increasing seizure threshold, but markedly more tolerable in both species. Effective doses of imepitoin in the PTZ seizure model were in the same range as those suppressing spontaneous recurrent seizures in epileptic dogs. The study demonstrates that low-affinity partial agonists at the benzodiazepine site of the GABAA receptor, such as imepitoin, offer advantages as a new category of AEDs.
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine, Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany. Electronic address: wolfgang.loescher@tiho-hannover.de.
Wolfgang
W
Löscher
Katrin
K
Hoffmann
Friederike
F
Twele
Heidrun
H
Potschka
Kathrin
K
Töllner
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002243:Carbolines / Q000819:agonists / Q000627:therapeutic use; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D054333:Drug Partial Agonism; D005260:Female; D058785:GABA-A Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D010433:Pentylenetetrazole; D010634:Phenobarbital / Q000097:blood / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*
C116306:AWD 131-138; D000927:Anticonvulsants; D002243:Carbolines; D058785:GABA-A Receptor Agonists; D007093:Imidazoles; C062769:abecarnil; D010433:Pentylenetetrazole; D010634:Phenobarbital
ADD; AED; ASP; Antiepileptic Drug Development; Antiepileptic drugs; BZD; Benzodiazepine binding site; CLZ; DZP; Epilepsy; GABA receptor; Imepitoin; NIH; NINDS; National Institute of Neurological Disorders and Stroke; National Institutes of Health; PB; PTZ; Pentylenetetrazole; TD; TIC; TID; VPA; anticonvulsant screening programme; antiepileptic drug; benzodiazepine; clonazepam; diazepam; pentylenetetrazole; phenobarbital; threshold increasing concentration; threshold increasing dose; toxic dose; valproate